Detection and clinical significance of combined measurement of serum tumor markers in patients with lung cancer

Objective To study the clinical diagnosis value and the clinical significance of combined measurement of CEA, DR70, NSE and CYFRA21- 1 in patients with lung cancer. Methods The serum levels of CEA, DR70, NSE and CYFRA21- 1 were determined by ELISA in 130 patients with lung cancer, 50 patients with benign pulmonary disease and 100 cases of normal controls. Results The levels of serum CEA, DR70, NSE and CYFRA21- 1 in lung cancer patients were significantly higher than that in benign pulmonary disease patients and controls (P 0.01 respectively). The CEA level of adenocarcinoma was significantly higher than that of the other pathology types, and the NSE level of SCLC was significantly higher than that of the other pathology types. The 4 tumor markers levels of the patients of CR and PR after treatment were significantly lower than that before treatment. The sensitivity (73.1 %) of combined detection were significantly higher than that of the every single item(45.4 %, 24.6 %, 36.2 %, 33.8 % respectively),and the veracity (80.5 %) of combined detection were significantly higher than that of the every single item (65.7 %, 55.2 %, 63.5 %, 60.7 % respectively). Conclusions The results indicate that the combined use of CEA, DR70, NSE and CYFRA21- 1 can increase the diagnostic sensitivity of lung cancer. It is an useful adjunct measure for differentiation of the pathology types, and it is helpful in the evaluation of prognosis and clinical therapy effect.